The recent novel coronavirus (COVID-19) outbreak, originating from China, is rampaging across the globe. According to the Worldometers, global coronavirus cases reached over 1.4 million with death toll around 83,000 as of 8th April 2020. With nearly 400,500 infected persons, the US is majorly affected due to the virus spread. The US followed by Spain and Italy with cases around 146,690 and 135,586 respectively as of 8th April 2020. With no vaccine in place, the governments of several nations have taken precautionary measures to lower the spread of the virus. The spread of the deadliest virus has forced the government of several nations to lock down streets, cities, and states of the country. Cinema halls, restaurants, cafeterias, pubs, bars, and other entertainment places have been shut down so as to keep people away from social distancing.

On the other hand, several pharmaceutical players have begun to put efforts on the R&D of innovative drugs and vaccines for the treatment of COVID-19. As the commercialization of vaccines solely for the treatment of COVID-19 is seen too far from the outbreak date, numbers of research organizations are working with the World Health Organization (WHO) to conduct clinical trials of existing antiviral drugs to treat patients suffering from COVID-19. As an instance, the WHO has collaborated with the researchers in China to conduct clinical trials of existing antiviral medications to treat patients infected with COVID-19. In February 2020, trials have been launched in China to determine the efficacy and safety of existing antiviral therapies, namely nucleotide analog remdesivir and HIV combination therapy Kaletra (the combination of lopinavir and ritonavir). Nucleotide analog remdesivir is formulated by Gilead Sciences, Inc. which is already under development for Ebola, and the later drug is formulated by AbbVie Inc.

China expects to have the first COVID-19 vaccine to be ready for clinical trials by the end of April 2020, as stated by the Xu Nanping, China’s vice-minister of science and technology. The US-based pharmaceutical firm Inovio Pharmaceuticals plans to begin clinical trials on a COVID-19 vaccine in April 2020. Moreover, on 19th March 2020, chloroquine and hydroxychloroquine drugs have been approved by the US Food and Drug Administration (FDA) for limited emergency use for the treatment for COVID-19. Government agencies are further planning to test other antiviral drugs for coronavirus treatment. Further, on 21st February 2020, Favilavir, an anti-viral drug, has been approved by the National Medical Products Administration of China as the treatment for coronavirus. 

COVID-19 vaccines under development

• Fusogenix DNA vaccine is under development by the Entos Pharmaceutical. Entos is using the Fusogenix drug delivery platform to prevent COVID-19 infections. 
• The University of Oxford is working on the development of the ChAdOx1 nCoV-19 vaccine. It is an adenovirus vaccine vector being developed by the Jenner Institute of the university. The university plans to test the vaccine in a clinical trial to be conducted in the Thames Valley Region with nearly 510 enrollments aged between 18 years and 55 years. 
• Roivant Sciences is accelerating the development of the Gimsilumab drug. The drug targets granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a pro-inflammatory cytokine found in high levels in the serum of COVID-19 patients. By targeting GM-CSF, reduced lung damage, and reduced mortality rate in COVID-19 patients can be expected.
• On 30th March 2020, the University of Alabama at Birmingham (UAB) has announced to collaborate with Altimmune to develop AdCOVID, a single dose intranasal vaccine for novel coronavirus. UAB and Altimmune will work closely with researchers to conduct preclinical animal studies and phase-I clinical trial in the third quarter of 2020. 
• TJM2, a neutralizing antibody, is being developed by I-Mab Biopharma as a treatment for coronavirus infected patients. The drug targets the human GM-CSF which is responsible for acute and chronic inflammation. The company expects to commence development after receiving approval for the Investigational New Drug (IND) application from the US FDA.

Research Methodology

The study on the global COVID-19 pipeline assessment is incorporated by extensive primary and secondary research conducted by the research team. In secondary research, different approaches have been adopted to derive the market value, market growth rate, and analyze trends in the industry due to the COVID-19 pandemic. In the report, the analysis of the country is provided by analyzing various regional players, laws & policies, consumer behavior, macro-economic factors, and impact of the pandemic. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures. 

Sources Include

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog
• Government Organizations Reports

The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

The Report Covers

• Comprehensive research methodology of the global COVID-19 pipeline assessment.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key findings and recommendations.
• Analysis of regional regulations and government funding impacting the global COVID-19 pipeline assessment.
• Insights about market determinants that are stimulating the global COVID-19 pipeline assessment.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.